Alector Announces Pricing of Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) — Alector, Inc. (Nasdaq:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the pricing of an underwritten public offering of 10,869,566 shares of its common stock for total gross proceeds of $75 million before deducting underwriting discounts and commissions and estimated offering expenses payable by Alector. The offering is expected to close on January 19, 2024, subject to satisfaction of customary closing conditions. All of the shares in the offering are being sold by Alector.
Related news for (ALEC)
- Don’t Miss Out: MoBot’s Latest Stock Updates 08/08/25 03:00 PM
- Alector Provides Executive Leadership Update
- Alector Reports First Quarter 2025 Financial Results and Provides Business Update
- Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer’s Disease
- Alector Provides Executive Leadership Update